Activity ratios measure how efficiently a company performs day-to-day tasks, such us the collection of receivables and management of inventory.
Short-term Activity Ratios (Summary)
Turnover Ratios
Average No. Days
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
An analysis of the operating activity ratios reveals a general trend toward increased efficiency in the management of short-term assets and liabilities over the observed period from March 2022 through September 2026.
- Receivables Management
- A positive trajectory is observed in the receivables turnover ratio, which increased from 15.65 in March 2022 to a peak of 21.69 by September 2026. This correlates with a reduction in the average receivable collection period, which declined from 23 days to 17 days. Periodic fluctuations are evident, particularly during the first quarter of each year, where collection periods typically lengthen—reaching peaks of 25 and 26 days in March 2023 and March 2024, respectively—before contracting in subsequent quarters. This indicates a recurring seasonal pattern in revenue collection.
- Payables Management
- Payables turnover demonstrates a gradual and steady increase, moving from 6.78 in March 2022 to 7.82 in September 2026. Concurrently, the average payables payment period has tightened, decreasing from 54 days to 47 days. Unlike the receivables metrics, payables activity shows significantly less volatility, suggesting a consistent and stable strategy in managing obligations to vendors and suppliers.
- Operational Cycle Implications
- The simultaneous reduction in both the collection and payment periods indicates an acceleration of the overall operating cycle. The more pronounced improvement in the receivables collection speed relative to the moderate decrease in the payables payment period suggests a strengthened ability to convert credit sales into cash more rapidly, thereby enhancing short-term liquidity.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Receivables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Revenues, customers | 111,617) | 110,809) | 110,590) | 112,568) | 112,029) | 110,508) | 108,542) | 99,256) | 99,177) | 97,858) | 98,785) | 93,248) | 91,364) | 91,788) | 91,133) | 81,932) | 80,381) | 80,037) | 79,782) | ||||||
| Accounts receivable, net | 20,543) | 21,573) | 26,587) | 23,018) | 22,672) | 24,142) | 26,936) | 22,365) | 20,024) | 23,115) | 27,197) | 21,276) | 20,673) | 17,952) | 22,414) | 17,681) | 17,047) | 18,718) | 18,871) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Receivables turnover1 | 21.69 | 20.67 | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Receivables Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 5.42 | 5.50 | 5.59 | 5.39 | 5.41 | 5.78 | 6.06 | 5.85 | 5.94 | 6.11 | 6.11 | 6.15 | 6.52 | 6.89 | 7.02 | 7.03 | 6.33 | 6.20 | ||||||
| Elevance Health Inc. | 15.41 | 14.99 | 14.30 | 16.34 | 16.80 | 14.83 | 14.42 | 18.00 | 19.84 | 17.60 | 15.98 | 18.08 | 17.93 | 18.82 | 16.53 | 18.81 | 19.51 | 18.80 | 16.67 | ||||||
| Intuitive Surgical Inc. | 6.73 | 6.59 | 6.63 | 6.59 | 7.63 | 7.21 | 7.13 | 6.82 | 6.82 | 6.83 | 6.49 | 6.30 | 7.12 | 7.37 | 6.95 | 6.60 | 7.20 | 7.11 | 6.52 | ||||||
| Medtronic PLC | 5.58 | 5.44 | 5.46 | 5.15 | 5.43 | 5.27 | 5.42 | 5.28 | 5.42 | 5.39 | 5.44 | 5.21 | 5.23 | 5.48 | 5.85 | 5.71 | 5.84 | 5.79 | 5.82 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Receivables turnover
= (Revenues, customersQ3 2026
+ Revenues, customersQ2 2026
+ Revenues, customersQ1 2026
+ Revenues, customersQ4 2025)
÷ Accounts receivable, net
= (111,617 + 110,809 + 110,590 + 112,568)
÷ 20,543 = 21.69
2 Click competitor name to see calculations.
An analysis of revenue and accounts receivable metrics indicates a sustained growth trajectory in top-line performance coupled with cyclical volatility in receivables management over the observed period.
- Revenue Trends
- Customer revenues exhibit a consistent upward trend, increasing from 79,782 million USD in March 2022 to 111,617 million USD by September 2026. Significant growth increments are observed between December 2022 and March 2023, and again in the first quarter of 2025, reflecting a robust expansion of the revenue base.
- Accounts Receivable Dynamics
- Net accounts receivable demonstrate significant quarterly fluctuations characterized by a recurring seasonal pattern. Receivables typically peak during the first quarter of each year—most notably in March 2024 at 27,197 million USD and March 2025 at 26,936 million USD—followed by a contraction in the subsequent quarters. This volatility suggests periodic shifts in billing cycles or collection timings.
- Receivables Turnover Efficiency
- The receivables turnover ratio fluctuates in inverse correlation with the peaks in net accounts receivable. A cyclical dip in efficiency is consistently recorded every March, reaching a period low of 13.80 in March 2024. However, an overall improving trend in collection velocity is evident, with the ratio reaching its peak of 21.69 in September 2026. This indicates that despite short-term volatility, the ability to convert receivables into cash has strengthened over the long term.
The data suggests a operational pattern where revenue growth is steady, but the efficiency of the collection process is subject to quarterly seasonality. The upward trajectory of the turnover ratio toward the end of the period indicates an optimization of working capital management relative to the increased revenue volume.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Payables Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Medical costs | 76,982) | 75,358) | 73,489) | 82,041) | 79,958) | 78,585) | 73,411) | 67,035) | 65,957) | 65,458) | 65,735) | 62,231) | 59,550) | 60,268) | 59,845) | 53,591) | 52,635) | 52,093) | 52,523) | ||||||
| Medical costs payable | 39,352) | 38,930) | 39,659) | 39,337) | 40,181) | 38,427) | 37,136) | 34,224) | 33,951) | 32,547) | 34,032) | 32,395) | 32,792) | 31,947) | 31,809) | 29,056) | 29,064) | 28,978) | 28,676) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Payables turnover1 | 7.82 | 7.98 | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Payables Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 4.22 | 4.22 | 4.56 | 4.69 | 4.40 | 4.44 | 4.46 | 4.54 | 4.42 | 4.33 | 4.19 | 4.55 | 4.28 | 4.44 | 4.15 | 4.67 | 4.25 | 4.02 | ||||||
| Elevance Health Inc. | 8.05 | 8.06 | 8.06 | 8.68 | 8.38 | 8.07 | 7.87 | 8.10 | 8.17 | 8.09 | 7.54 | 7.72 | 7.61 | 7.54 | 7.57 | 7.47 | 7.48 | 7.35 | 7.28 | ||||||
| Intuitive Surgical Inc. | 13.59 | 13.26 | 10.71 | 13.42 | 11.10 | 11.44 | 10.39 | 14.05 | 11.88 | 12.91 | 12.64 | 12.69 | 11.66 | 11.10 | 12.99 | 13.78 | 12.01 | 12.68 | 14.36 | ||||||
| Medtronic PLC | 4.85 | 4.64 | 4.65 | 4.75 | 5.04 | 4.85 | 4.95 | 4.65 | 5.60 | 5.09 | 4.84 | 4.03 | 4.68 | 4.60 | 4.62 | 4.46 | 5.14 | 5.41 | 5.67 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Payables turnover
= (Medical costsQ3 2026
+ Medical costsQ2 2026
+ Medical costsQ1 2026
+ Medical costsQ4 2025)
÷ Medical costs payable
= (76,982 + 75,358 + 73,489 + 82,041)
÷ 39,352 = 7.82
2 Click competitor name to see calculations.
Analysis of medical costs and payables turnover reveals a general upward trajectory in both operational expenditures and settlement efficiency over the period from March 2022 to September 2026.
- Medical Costs and Payables Expansion
- A consistent increase in medical costs is observed, rising from 52,523 million USD in March 2022 to 76,982 million USD by September 2026. Concurrently, medical costs payable increased from 28,676 million USD to 39,352 million USD. While both metrics grew, the growth in quarterly medical costs outpaced the growth in the payable balance, contributing to an overall increase in the turnover ratio.
- Payables Turnover Trend
- The payables turnover ratio demonstrates a long-term positive trend, increasing from 6.78 in March 2022 to a peak of 7.98 in December 2025 and June 2026. The ratio experienced moderate volatility during 2023, falling to 6.86 in March before recovering to 7.47 by year-end. A more sustained period of growth occurred throughout 2024, during which the ratio ascended from 7.28 in March to 7.72 by December.
- Operational Efficiency and Stability
- The upward movement of the turnover ratio indicates an acceleration in the rate at which medical obligations are settled relative to the average payables held. By 2026, the ratio stabilized at a higher baseline, fluctuating narrowly between 7.82 and 7.98. This suggests a more streamlined processing cycle for medical costs compared to the baseline observed in the 2022-2023 period.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Working Capital Turnover
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data (US$ in millions) | |||||||||||||||||||||||||
| Current assets | 85,595) | 86,860) | 91,127) | 90,582) | 95,067) | 93,699) | 96,285) | 85,779) | 92,258) | 92,038) | 88,942) | 78,437) | 91,905) | 89,869) | 93,895) | 69,069) | 82,937) | 68,356) | 69,029) | ||||||
| Less: Current liabilities | 115,835) | 111,820) | 114,124) | 114,897) | 115,526) | 110,781) | 113,471) | 103,769) | 101,565) | 104,670) | 104,431) | 99,054) | 114,179) | 112,981) | 116,482) | 89,237) | 100,935) | 88,698) | 88,170) | ||||||
| Working capital | (30,240) | (24,960) | (22,997) | (24,315) | (20,459) | (17,082) | (17,186) | (17,990) | (9,307) | (12,632) | (15,489) | (20,617) | (22,274) | (23,112) | (22,587) | (20,168) | (17,998) | (20,342) | (19,141) | ||||||
| Revenues, customers | 111,617) | 110,809) | 110,590) | 112,568) | 112,029) | 110,508) | 108,542) | 99,256) | 99,177) | 97,858) | 98,785) | 93,248) | 91,364) | 91,788) | 91,133) | 81,932) | 80,381) | 80,037) | 79,782) | ||||||
| Short-term Activity Ratio | |||||||||||||||||||||||||
| Working capital turnover1 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | ||||||
| Benchmarks | |||||||||||||||||||||||||
| Working Capital Turnover, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 6.95 | 6.33 | 4.67 | 4.27 | 3.91 | 4.17 | 4.42 | 4.63 | 4.35 | 4.83 | 4.54 | 4.15 | 4.39 | 4.21 | 4.48 | 3.92 | 3.63 | 4.13 | ||||||
| Elevance Health Inc. | 7.53 | 7.19 | 7.59 | 7.50 | 7.00 | 7.96 | 8.11 | 7.85 | 6.87 | 6.92 | 8.59 | 7.83 | 7.92 | 7.69 | 7.60 | 8.37 | 9.11 | 8.85 | 8.65 | ||||||
| Intuitive Surgical Inc. | 1.96 | 1.45 | 1.53 | 1.29 | 1.43 | 1.30 | 1.42 | 1.56 | 1.42 | 1.23 | 1.17 | 1.14 | 0.95 | 1.03 | 1.15 | 1.29 | 1.21 | 1.17 | 1.26 | ||||||
| Medtronic PLC | 2.43 | 2.47 | 2.92 | 3.07 | 3.11 | 3.22 | 2.79 | 2.90 | 2.54 | 2.57 | 2.46 | 2.47 | 2.81 | 2.82 | 3.84 | 2.97 | 2.21 | 2.13 | 2.15 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Working capital turnover
= (Revenues, customersQ3 2026
+ Revenues, customersQ2 2026
+ Revenues, customersQ1 2026
+ Revenues, customersQ4 2025)
÷ Working capital
= (111,617 + 110,809 + 110,590 + 112,568)
÷ -30,240 = —
2 Click competitor name to see calculations.
Financial performance over the analyzed period is characterized by a sustained increase in quarterly revenues paired with a consistently negative working capital position. Revenues demonstrated a steady upward trajectory, rising from 79,782 million USD in March 2022 to 111,617 million USD by September 2026.
- Working Capital Trends
- Working capital remained negative throughout the entire observation period, indicating that current liabilities consistently exceeded current assets. Between March 2022 and December 2023, the deficit generally fluctuated between -17.9 billion USD and -23.1 billion USD. A notable contraction of this deficit occurred during 2024, where working capital reached its least negative point of -9,307 million USD in September 2024. This trend reversed starting in December 2024, with the negative position widening progressively to reach its lowest point of -30,240 million USD by September 2026.
- Working Capital Turnover Interpretation
- The working capital turnover ratio reflects the interaction between rising revenues and a volatile negative working capital base. For the duration of 2022 and 2023, the ratio remained relatively stable, typically ranging between -3.9 and -4.5. In 2024, the significant reduction in the working capital deficit caused the turnover ratio to spike, reaching a peak of -10.66 in September 2024. As the negative working capital position expanded again throughout 2025 and 2026, the turnover ratio trended back toward lower magnitudes, concluding at -3.69 in September 2026.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Receivable Collection Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Receivables turnover | 21.69 | 20.67 | 16.76 | 19.27 | 18.98 | 17.29 | 15.03 | 17.66 | 19.43 | 16.49 | 13.80 | 17.27 | 17.23 | 19.23 | 14.88 | 18.22 | 18.37 | 16.27 | 15.65 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average receivable collection period1 | 17 | 18 | 22 | 19 | 19 | 21 | 24 | 21 | 19 | 22 | 26 | 21 | 21 | 19 | 25 | 20 | 20 | 22 | 23 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Receivable Collection Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 67 | 66 | 65 | 68 | 67 | 63 | 60 | 62 | 61 | 60 | 60 | 59 | 56 | 53 | 52 | 52 | 58 | 59 | ||||||
| Elevance Health Inc. | 24 | 24 | 26 | 22 | 22 | 25 | 25 | 20 | 18 | 21 | 23 | 20 | 20 | 19 | 22 | 19 | 19 | 19 | 22 | ||||||
| Intuitive Surgical Inc. | 54 | 55 | 55 | 55 | 48 | 51 | 51 | 54 | 53 | 53 | 56 | 58 | 51 | 50 | 53 | 55 | 51 | 51 | 56 | ||||||
| Medtronic PLC | 65 | 67 | 67 | 71 | 67 | 69 | 67 | 69 | 67 | 68 | 67 | 70 | 70 | 67 | 62 | 64 | 63 | 63 | 63 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average receivable collection period = 365 ÷ Receivables turnover
= 365 ÷ 21.69 = 17
2 Click competitor name to see calculations.
The analysis of short-term operating activity reveals a general improvement in the efficiency of receivables management over the period from March 2022 to September 2026. An inverse correlation is maintained between the receivables turnover ratio and the average collection period, with the overall trend indicating an acceleration in the conversion of receivables into cash.
- Receivables Turnover Trends
- The receivables turnover ratio exhibits a long-term upward trajectory, increasing from 15.65 in March 2022 to a peak of 21.69 by September 2026. While the growth was not linear, the ratio demonstrates a strengthening ability to collect outstanding debts relative to credit sales. Notable periodic dips occurred in March 2023 (14.88) and March 2024 (13.80), followed by consistent recoveries in the subsequent quarters.
- Average Receivable Collection Period
- The average collection period shows a corresponding downward trend, starting at 23 days in March 2022 and concluding at 17 days in September 2026. This reduction signifies a more efficient credit collection process and a shorter cash conversion cycle. The most significant efficiency gains are observed toward the end of the analyzed period, where the collection period remained consistently below 20 days from June 2025 onward.
- Seasonal Cyclicality
- A recurring seasonal pattern is evident in the first quarter of each year. The average collection period consistently peaks in March, with values reaching 25 days in 2023, 26 days in 2024, 24 days in 2025, and 22 days in 2026. These periodic increases in the collection window suggest a systemic quarterly fluctuation in payment timing or billing cycles, although the magnitude of these peaks has gradually diminished over time.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?
Average Payables Payment Period
| Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 | Sep 30, 2023 | Jun 30, 2023 | Mar 31, 2023 | Dec 31, 2022 | Sep 30, 2022 | Jun 30, 2022 | Mar 31, 2022 | |||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Selected Financial Data | |||||||||||||||||||||||||
| Payables turnover | 7.82 | 7.98 | 7.92 | 7.98 | 7.44 | 7.42 | 7.32 | 7.72 | 7.64 | 7.77 | 7.28 | 7.47 | 7.11 | 7.08 | 6.86 | 7.26 | 7.07 | 6.90 | 6.78 | ||||||
| Short-term Activity Ratio (no. days) | |||||||||||||||||||||||||
| Average payables payment period1 | 47 | 46 | 46 | 46 | 49 | 49 | 50 | 47 | 48 | 47 | 50 | 49 | 51 | 52 | 53 | 50 | 52 | 53 | 54 | ||||||
| Benchmarks (no. days) | |||||||||||||||||||||||||
| Average Payables Payment Period, Competitors2 | |||||||||||||||||||||||||
| Abbott Laboratories | — | 87 | 87 | 80 | 78 | 83 | 82 | 82 | 80 | 83 | 84 | 87 | 80 | 85 | 82 | 88 | 78 | 86 | 91 | ||||||
| Elevance Health Inc. | 45 | 45 | 45 | 42 | 44 | 45 | 46 | 45 | 45 | 45 | 48 | 47 | 48 | 48 | 48 | 49 | 49 | 50 | 50 | ||||||
| Intuitive Surgical Inc. | 27 | 28 | 34 | 27 | 33 | 32 | 35 | 26 | 31 | 28 | 29 | 29 | 31 | 33 | 28 | 26 | 30 | 29 | 25 | ||||||
| Medtronic PLC | 75 | 79 | 79 | 77 | 72 | 75 | 74 | 78 | 65 | 72 | 75 | 91 | 78 | 79 | 79 | 82 | 71 | 67 | 64 | ||||||
Based on: 10-Q (reporting date: 2026-09-30), 10-Q (reporting date: 2026-06-30), 10-Q (reporting date: 2026-03-31), 10-K (reporting date: 2025-12-31), 10-Q (reporting date: 2025-09-30), 10-Q (reporting date: 2025-06-30), 10-Q (reporting date: 2025-03-31), 10-K (reporting date: 2024-12-31), 10-Q (reporting date: 2024-09-30), 10-Q (reporting date: 2024-06-30), 10-Q (reporting date: 2024-03-31), 10-K (reporting date: 2023-12-31), 10-Q (reporting date: 2023-09-30), 10-Q (reporting date: 2023-06-30), 10-Q (reporting date: 2023-03-31), 10-K (reporting date: 2022-12-31), 10-Q (reporting date: 2022-09-30), 10-Q (reporting date: 2022-06-30), 10-Q (reporting date: 2022-03-31).
1 Q3 2026 Calculation
Average payables payment period = 365 ÷ Payables turnover
= 365 ÷ 7.82 = 47
2 Click competitor name to see calculations.
The analysis of short-term operating activity indicates a consistent acceleration in the settlement of obligations to suppliers over the observed period. There is a clear inverse relationship between the payables turnover ratio and the average payables payment period, reflecting a shift toward more frequent payment cycles and a reduction in the duration of outstanding liabilities.
- Payables Turnover Trend
- The payables turnover ratio demonstrates a steady upward trajectory, increasing from 6.78 in March 2022 to 7.82 by September 2026. This progression suggests an increase in the frequency with which the company clears its average accounts payable. Peak turnover values of 7.98 were recorded in December 2025 and June 2026, signaling the highest levels of payment velocity within the analyzed timeframe.
- Average Payables Payment Period
- The average time required to settle payables has contracted from a high of 54 days in March 2022 to 47 days by September 2026. A notable trend of decline is evident, with the period reaching its minimum of 46 days between December 2025 and June 2026. This reduction implies a diminished reliance on supplier credit to fund short-term operations and a more aggressive approach to liability management.
- Operational Patterns and Volatility
- Initial data from early 2022 through early 2023 shows moderate volatility, with the payment period fluctuating between 50 and 54 days. However, starting in mid-2023, a more consistent downward trend emerged. The transition from a 50-day average in March 2024 to a sustained 46-47 day range in 2026 indicates a structural change in the company's cash disbursement timing.
AI Ask an analyst for more
Hi, I’m an AI-powered financial analyst at Stock Analysis on Net.
Without a user account, I tend to respond rather slowly.
How can I help you?